Feasibility of using SmartMatch for guiding treatment options in rare gynecologic cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study collects tissue from standard-of-care procedures and reviews medical records to see how feasible SmartMatch analysis is in guiding treatment for metastatic or unresectable rare gynecologic tumors. It does not mandate any specific therapy as part of the protocol; instead, it assesses the practicality of integrating SmartMatch into routine care. Eligible participants are adults with histologically confirmed rare gynecologic cancers, adequate organ function, and the ability to consent. The study focuses on feasibility and data abstraction rather than testing a particular therapeutic intervention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* Histologically confirmed rare gynecologic malignancy, including but not limited to those listed
* Metastatic or unresectable disease, OR disease for which additional systemic therapy is indicated
* Fresh tumor tissue available from a SOC surgical procedure or biopsy that in the judgment of the treating team will yield adequate viable tumor for SmartMatch analysis
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Adequate organ function to receive systemic therapy as determined by the treating oncologist (protocol does not specify thresholds because therapy is not mandated)
* Ability to understand and willingness to sign informed consent
* Willingness to allow data abstraction from the electronic health record for study endpoints

Exclusion Criteria:

* Lack of tumor tissue suitable for SmartMatch analysis
* Purely borderline tumors or benign ovarian/uterine neoplasms
* Any condition that, in the opinion of the treating oncologist or PI, would interfere with receiving systemic therapy
* Inability to provide informed consent or comply with study procedures

Where it's running

• Fred Hutch/University of Washington Cancer Consortium
  Seattle, Washington, United States Recruiting

Study contacts

• Principal investigator: Kalyan Banda, MD — Fred Hutch/University of Washington Cancer Consortium
• Study coordinator: Kalyan Banda, MD
• Email: bkalyan@uw.edu
• Phone: 206-606-2222

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blended e-Health Program to Help Women with Breast or Gynecologic Cancer Manage Fear of Cancer Progression

  This trial tests a blended online and group program to see if it helps women with breast or gynecologic cancer feel less fear that their cancer could grow or spread.

  Recruiting at 11 sites City of Hope Medical Center · Arcadia, California and 10 other locations · NCT07741968

• Vaginal DHEA to improve vaginal health after pelvic radiation

  This phase II trial tests whether daily vaginal DHEA can help reduce vaginal dryness, pain, and related symptoms in menopausal women after radiation for gynecologic, anal, or rectal cancers.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07407647

• Using fucoidan to prevent fatigue in cancer patients undergoing chemotherapy

  This study tests if a seaweed supplement called fucoidan can help cancer patients undergoing chemotherapy feel less tired.

  Recruiting Phase 2 Mayo Clinic · Scottsdale, Arizona · NCT06855524

• Personalized online home walking program for women after gynecologic cancer

  This trial will test whether a personalized online home walking program can help gynecologic cancer survivors reduce pain, fatigue, sleep problems, depression, cognitive difficulties, and alter gut bacteria.

  Recruiting at 4 sites Emory University · Atlanta, Georgia and 3 other locations · NCT06709534

• Comparing methadone and hydromorphone for pain relief after gynecologic cancer surgery

  This study is testing whether methadone can provide similar pain relief as hydromorphone for patients recovering from gynecologic cancer surgery.

  Recruiting Phase 4 Mayo Clinic · Rochester, Minnesota · NCT06525740

• Testing neratinib alone or with palbociclib for HER2 positive solid tumors

  This study is testing if a new cancer treatment called neratinib works better alone or with another drug, palbociclib, for people with HER2 positive solid tumors, especially those with gynecologic cancers.

  Recruiting at 181 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 193 other locations · NCT06126276

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.